FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4288032971> ?p ?o ?g. }

• W4288032971 endingPage "567" @default.
• W4288032971 startingPage "559" @default.
• W4288032971 abstract "Sodium-glucose co-transporter-2 (SGLT2) inhibitors improve outcomes among patients with established heart failure. Despite supportive basic science studies, there are no data on the value of SGLT2 inhibitors among patients treated with anthracyclines.This study sought to test the cardiac efficacy and overall safety of SGLT2 inhibitors in patients treated with anthracyclines.This study identified 3,033 patients with diabetes mellitus (DM) and cancer who were treated with anthracyclines. Cases were patients with cancer and DM who were on SGLT2 inhibitor therapy during anthracycline treatment (n = 32). Control participants (n = 96) were patients with cancer and DM who were also treated with anthracyclines, but were not on an SGLT2 inhibitor. The primary cardiac outcome was a composite of cardiac events (heart failure incidence, heart failure admissions, new cardiomyopathy [>10% decline in ejection fraction to <53%], and clinically significant arrhythmias). The primary safety outcome was overall mortality.Age, sex, ethnicity, cancer type, cancer stage, and other cardiac risk factors were similar between groups. There were 20 cardiac events over a median follow-up period of 1.5 years. The cardiac event incidence was lower among case patients in comparison to control participants (3% vs 20%; P = 0.025). Case patients also experienced lower overall mortality when compared with control participants (9% vs 43%; P < 0.001) and a lower composite of sepsis and neutropenic fever (16% vs 40%; P = 0.013).SGLT2 inhibitors were associated with lower rate of cardiac events among patients with cancer and DM who were treated with anthracyclines. Additionally, SGLT2 inhibitors appeared to be safe. These data support the conducting of a randomized clinical trial testing SGLT2 inhibitors in patients at high cardiac risk treated with anthracyclines." @default.
• W4288032971 created "2022-07-27" @default.
• W4288032971 creator A5000990055 @default.
• W4288032971 creator A5001986733 @default.
• W4288032971 creator A5002079265 @default.
• W4288032971 creator A5002103749 @default.
• W4288032971 creator A5011648025 @default.
• W4288032971 creator A5014010667 @default.
• W4288032971 creator A5017972924 @default.
• W4288032971 creator A5035186913 @default.
• W4288032971 creator A5037736695 @default.
• W4288032971 creator A5048612025 @default.
• W4288032971 creator A5054544773 @default.
• W4288032971 creator A5055724348 @default.
• W4288032971 creator A5066923122 @default.
• W4288032971 creator A5068710430 @default.
• W4288032971 creator A5069837934 @default.
• W4288032971 creator A5075396473 @default.
• W4288032971 creator A5076038933 @default.
• W4288032971 creator A5084378579 @default.
• W4288032971 creator A5087164932 @default.
• W4288032971 date "2022-08-01" @default.
• W4288032971 modified "2023-10-17" @default.
• W4288032971 title "Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines" @default.
• W4288032971 cites W1537090860 @default.
• W4288032971 cites W2037706689 @default.
• W4288032971 cites W2051357882 @default.
• W4288032971 cites W2065495412 @default.
• W4288032971 cites W2091238429 @default.
• W4288032971 cites W2167777123 @default.
• W4288032971 cites W2516478359 @default.
• W4288032971 cites W2739126694 @default.
• W4288032971 cites W2800603965 @default.
• W4288032971 cites W2813959471 @default.
• W4288032971 cites W2818636544 @default.
• W4288032971 cites W2889422847 @default.
• W4288032971 cites W2899764361 @default.
• W4288032971 cites W2901781577 @default.
• W4288032971 cites W2902044664 @default.
• W4288032971 cites W2911752236 @default.
• W4288032971 cites W2913306188 @default.
• W4288032971 cites W2936553968 @default.
• W4288032971 cites W2966319220 @default.
• W4288032971 cites W2966426030 @default.
• W4288032971 cites W2974260792 @default.
• W4288032971 cites W2980072629 @default.
• W4288032971 cites W2985670977 @default.
• W4288032971 cites W2990574617 @default.
• W4288032971 cites W2996729736 @default.
• W4288032971 cites W2999431040 @default.
• W4288032971 cites W3027894455 @default.
• W4288032971 cites W3043378534 @default.
• W4288032971 cites W3073811870 @default.
• W4288032971 cites W3082758064 @default.
• W4288032971 cites W3084081810 @default.
• W4288032971 cites W3093258912 @default.
• W4288032971 cites W3104942557 @default.
• W4288032971 cites W3121059516 @default.
• W4288032971 cites W3123572331 @default.
• W4288032971 cites W3141559619 @default.
• W4288032971 cites W95894433 @default.
• W4288032971 doi "https://doi.org/10.1016/j.jchf.2022.03.006" @default.
• W4288032971 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35902159" @default.
• W4288032971 hasPublicationYear "2022" @default.
• W4288032971 type Work @default.
• W4288032971 citedByCount "22" @default.
• W4288032971 countsByYear W42880329712022 @default.
• W4288032971 countsByYear W42880329712023 @default.
• W4288032971 crossrefType "journal-article" @default.
• W4288032971 hasAuthorship W4288032971A5000990055 @default.
• W4288032971 hasAuthorship W4288032971A5001986733 @default.
• W4288032971 hasAuthorship W4288032971A5002079265 @default.
• W4288032971 hasAuthorship W4288032971A5002103749 @default.
• W4288032971 hasAuthorship W4288032971A5011648025 @default.
• W4288032971 hasAuthorship W4288032971A5014010667 @default.
• W4288032971 hasAuthorship W4288032971A5017972924 @default.
• W4288032971 hasAuthorship W4288032971A5035186913 @default.
• W4288032971 hasAuthorship W4288032971A5037736695 @default.
• W4288032971 hasAuthorship W4288032971A5048612025 @default.
• W4288032971 hasAuthorship W4288032971A5054544773 @default.
• W4288032971 hasAuthorship W4288032971A5055724348 @default.
• W4288032971 hasAuthorship W4288032971A5066923122 @default.
• W4288032971 hasAuthorship W4288032971A5068710430 @default.
• W4288032971 hasAuthorship W4288032971A5069837934 @default.
• W4288032971 hasAuthorship W4288032971A5075396473 @default.
• W4288032971 hasAuthorship W4288032971A5076038933 @default.
• W4288032971 hasAuthorship W4288032971A5084378579 @default.
• W4288032971 hasAuthorship W4288032971A5087164932 @default.
• W4288032971 hasBestOaLocation W42880329711 @default.
• W4288032971 hasConcept C120665830 @default.
• W4288032971 hasConcept C121332964 @default.
• W4288032971 hasConcept C121608353 @default.
• W4288032971 hasConcept C126322002 @default.
• W4288032971 hasConcept C134018914 @default.
• W4288032971 hasConcept C164705383 @default.
• W4288032971 hasConcept C2776694085 @default.
• W4288032971 hasConcept C2778198053 @default.
• W4288032971 hasConcept C2778233292 @default.

• next